About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Insights - Hims & Hers Health is set to offer generic semaglutide in Canada as Novo Nordisk's patent on Ozempic and Wegovy is expiring in January [1][2] - The company aims to provide affordable and high-quality weight loss care, emphasizing accessibility and personalized care [2] - The Canadian semaglutide market generated $1.18 billion in 2024 and is projected to grow to $4.03 billion by 2035 [4] Company Strategy - Hims & Hers is entering the Canadian market for the first time, joining other drugmakers capitalizing on the expired patent of GLP-1 drugs [2] - The company is collaborating with an approved partner to ensure compliance with local laws and regulations regarding the generic semaglutide [5] Market Context - Generic semaglutide is a copy of the brand-name drugs Ozempic and Wegovy, offering the same efficacy and safety standards once the patent expires [3] - The approval process for generic semaglutide is underway in Canada, although no generic version has been approved yet [4][5]